Key Points
- This report aims to characterize the use and indications for implantable cardioverter defibrillators in pediatric and congenital heart disease patients.
- Data collected from the National Cardiovascular Data Registry from April 2010 to December 2012.
- Analysis of implantable cardioverter defibrillator procedures across two cohorts: patients with congenital heart disease and those under 21 years.
- Evaluation of lead types, CHD types, and New York Heart Association class.
- 1,601 procedures were performed for patients under 21 years, with primary prevention indicated in 935 cases (58.4%).
- Nontransvenous lead patients had a lower average age of 35.9 years compared to 40.1 years for transvenous patients (P=0.05).
- Patients with transposition of the great vessels and common ventricle showed higher rates of nontransvenous lead usage.
Structured PICO
PPopulationPatients undergoing implantable cardioverter defibrillator implantation in the National Cardiovascular Data Registry, including 3,139 procedures for congenital heart disease (CHD) and 1,601 for patients <21 years (126 with CHD <21 years).
IInterventionImplantable cardioverter defibrillator (ICD) implantation (transvenous and nontransvenous leads)
OOutcomeIndications and characteristics of ICD implants (including transvenous vs nontransvenous lead implants, CHD type, and New York Heart Association class)
In pediatric and congenital heart disease patients undergoing ICD implantation, primary prevention is the most common indication, and nontransvenous leads are used more frequently in younger, shorter patients and those with specific complex anatomies.